AtaiBeckley Inc (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company developing psychedelic and psychedelic-derived product candidates for mental health conditions. The company generates no product revenue, operating instead on external capital raises to fund its research and development pipeline. AtaiBeckley was formed through a strategic combination of atai Life Sciences and Beckley Psytech, and its product candidates contain controlled substances subject to strict regulatory requirements across jurisdictions. The company operates offices in New York, Berlin, London, and Montreal, as disclosed in its 10-K filed March 6, 2026. One disclosed partnership involves Invyxis, a wholly owned subsidiary, under an exclusive services and license agreement with Dalriada Drug Discovery Inc., under which Invyxis pays up to $7.4 million in service fees (as amended May 2023), plus development milestone payments and low single-digit royalties on net product sales. The company is listed on the Nasdaq Global Market.

Revenue model

Pre-revenue clinical-stage company. Funding comes from capital markets. One subsidiary arrangement with Dalriada Drug Discovery Inc. includes milestone payments and low single-digit royalties on future net product sales, contingent on regulatory approval.

Products and services

Pipeline of psychedelic-derived product candidates targeting mental health indications. Product candidates contain controlled substances subject to regulatory scheduling requirements. New chemical entities are being developed under the Invyxis-Dalriada collaboration.

Customers and end markets

No commercial customers disclosed. End market is mental health treatment, subject to FDA and comparable foreign regulatory approval before any commercialization.

Value-chain role

Drug developer relying on third-party contract manufacturers for production of product candidates. Regulatory approval required before any commercial activity.

Geographic exposure

Operations in New York, Berlin, London, and Montreal, as disclosed in the 10-K filed March 6, 2026. Subject to FDA oversight in the United States and comparable foreign authorities including the EMA in Europe.

Source: SEC 10-K, filed 2026-03-06

Industry: Pharmaceutical Preparations